Chronic migraine affects approximately 2% of the world's population. The World Health Organization classifies severe migraine attacks as among the most disabling invisible illnesses. Migraine affects three times as many women as men.

The direct and indirect costs of Chronic Migraine are significant at €95Bn to the EU.

Treatments start with pharmaceutical drugs, botox and nerve blockers which can be effective but often are expensive and have undesirable effects. Neurostimulation products that deliver electrical pulses have been up to 80% effective but are designed for the back, not the neck which results in high rates of surgical revisions. This leaves the chronic migraine population severely underserved.

Our ambition is to increase accessibility to treatment by reducing the cost and risk of associated medical interventions. TARA will develop 4 digital solutions that identify potential triggers and patterns to predict migraine episodes with higher accuracy.